The maximum possible contingent consideration under a licensing agreement.

No definition available.

Name:	nbrv_CollaborativeArrangementMaximumContingentConsideration
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount pertaining to milestone payment on collaborative arrangement.

+ References

No definition available.

+ Details

Name:	nbrv_CollaborativeArrangementMilestonePaymentReceived
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of a non-refundable upfront payment under a licensing agreement.

+ References

No definition available.

+ Details

Name:	nbrv_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of revenue recognized arising from contract liability for performance obligation was satisfied.

+ References

No definition available.

+ Details

Name:	nbrv_ContractWithCustomerLiabilityPerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was currently included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

No definition available.

+ Details

Name:	nbrv_ContractWithCustomerLiabilityRevenueRecognizedForAdditionsMadeDuringPeriod
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Notice period for termination of license agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	nbrv_NoticePeriodForTerminationOfLicenseAgreement
Namespace Prefix:	nbrv_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of representatives appointed.

+ References

No definition available.

+ Details

Name:	nbrv_NumberOfSalesRepresentatives
Namespace Prefix:	nbrv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of probability of achieving the future milestone payment.

+ References

No definition available.

+ Details

Name:	nbrv_ProbableOfAchievingMilestonePayment
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=nbrv_LicenseInitialPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbrv_SunovionPharmaceuticsCanadaInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_NdsApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbrv_SumitomoPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_AchievementOfCertainRegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_SubsequentRegulatoryApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_ClinicalTrialApplicationSubmissionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_FdaApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_ApprovalOfXenletaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_AdditionalRegulatoryApprovalsAndAnnualSalesTargetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Arrangements and License Agreements (Details) $ in Thousands		1 Months Ended				3 Months Ended						6 Months Ended
	Jul. 10, 2020 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2020 employee	Sep. 30, 2020 employee	Mar. 31, 2018 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	May 31, 2021 USD ($)
License Agreement
Revenue accounted for under Topic 606						$ 8,243			$ 487			$ 10,772	$ 1,276
Number Of Sales Representatives \| employee			60	15
Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606						6,940			$ (48)			$ 7,070	$ 108
Sunovion Pharmaceutics Canada, Inc. \| Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606					$ 1,000
License Agreement \| Sunovion Pharmaceutics Canada, Inc. \| NDS Approval
License Agreement
Revenue accounted for under Topic 606	$ 500
License Agreement \| Sumitomo Pharmaceuticals (Suzhou)
License Agreement
Upfront payment														$ 5,000
Notice period for termination of agreement												180 days
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| Achievement of certain regulatory and commercial milestones
License Agreement
Maximum contingent milestone payment														91,500
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| Subsequent regulatory approval
License Agreement
Maximum contingent milestone payment														$ 4,000
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| Clinical trial application submission
License Agreement
Proceeds from license agreement, milestone											$ 1,500
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| FDA approval
License Agreement
Revenue accounted for under Topic 606										$ 5,000
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| Approval of XENLETA
License Agreement
Revenue accounted for under Topic 606		$ 5,000
Remaining probable of achieving												$ 1,000
Additional revenue recognized												3,000
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| Additional regulatory approvals and annual sales targets
License Agreement
Remaining milestone payments						$ 86,000						86,000
License Agreement \| Sumitomo Pharmaceuticals (Suzhou) \| Collaboration revenue - Upfront payment
License Agreement
Revenue accounted for under Topic 606		$ 3,000						$ 1,000			$ 5,000
Milestone achieved							$ 1,000
Performance obligation												$ 1,300